ReviewBMJ global health2023
Tertiary prevention and treatment of rheumatic heart disease: a National Heart, Lung, and Blood Institute working group summary.
Review in BMJ global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Comparisons of the Burden and Quality of Care of Nonrheumatic Valvular Heart Disease in Asia and Globally.Journal of the American Heart Association · 2026Article
- Survival and mortality predictors among adults with rheumatic heart disease in ethiopia: a 10-year retrospective cohort study.BMC cardiovascular disorders · 2026Article
- Acute rheumatic fever and rheumatic heart disease.Nature reviews. Disease primers · 2026Review
- Long-Term Changes and Disparities in the Global Burden of Rheumatic Heart Disease between 1990 and 2021: An Analysis Based on the Global Burden of Disease (GBD) Study.Research in heart yield and translational medicine · 2026Article
- Global burden of rheumatic vs non-rheumatic valvular heart disease, 1990-2021: a systematic analysis of the global burden of disease study.Clinical rheumatology · 2025Article
- Practice and clinical outcomes of valvular surgery for rheumatic heart disease in africa: a scoping review.Journal of cardiothoracic surgery · 2025Article
- Cost-Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda.Journal of the American Heart Association · 2025Article
- Addressing the challenge of rheumatic heart disease in Pakistan: A call to action.Dialogues in health · 2025Article
- Redo surgery outcomes for obstructed replaced valve: a single-center experience.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
- AI prediction model for endovascular treatment of vertebrobasilar occlusion with atrial fibrillation.NPJ digital medicine · 2025Article
- One-year mortality and re-admission rate by disease etiology in National Heart Failure Registry of India.Nature communications · 2025Article
- Rheumatic Heart Disease Burden in Africa and the Need to Build Robust Infrastructure.JACC. Advances · 2024Review
- Making a difference: 5 years of Cardiac Surgery Intersociety Alliance (CSIA).European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2024Article
- Making a difference: 5 years of Cardiac Surgery Intersociety Alliance (CSIA).Asian cardiovascular & thoracic annals · 2024Article
- Prospects for the future: supporting the elimination of rheumatic heart disease - a National Heart, Lung, and Blood Institute Workshop Proceedings.BMJ global health · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 17 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although entirely preventable, rheumatic heart disease (RHD), a disease of poverty and social disadvantage resulting in high morbidity and mortality, remains an ever-present burden in low-income and middle-income countries (LMICs) and rural, remote, marginalised and disenfranchised populations within high-income countries. In late 2021, the National Heart, Lung, and Blood Institute convened a workshop to explore the current state of science, to identify basic science and clinical research priorities to support RHD eradication efforts worldwide. This was done through the inclusion of multidisciplinary global experts, including cardiovascular and non-cardiovascular specialists as well as health policy and health economics experts, many of whom also represented or closely worked with patient-family organisations and local governments. This report summarises findings from one of the four working groups, the Tertiary Prevention Working Group, that was charged with assessing the management of late complications of RHD, including surgical interventions for patients with RHD. Due to the high prevalence of RHD in LMICs, particular emphasis was made on gaining a better understanding of needs in the field from the perspectives of the patient, community, provider, health system and policy-maker. We outline priorities to support the development, and implementation of accessible, affordable and sustainable interventions in low-resource settings to manage RHD and related complications. These priorities and other interventions need to be adapted to and driven by local contexts and integrated into health systems to best meet the needs of local communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.